anti-CD40 ChiLob7/4

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameanti-CD40 ChiLob7/4

Drug Alias NameCD40 costimulator (BioNTech RNA Pharmaceuticals)anti-CD40 IS-Ab ChiLob7/4antibodies IACT project (BioNTech)anti-CD40 MAb IACT project (BioNTech)ChiLob 7/4

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody

Mechanisms of ActionTumor necrosis factor receptor superfamily member 5 agonists

TargetsTumor necrosis factor receptor superfamily member 5

Therapy Area/IndicationsHead and Neck NeoplasmsPancreatic NeoplasmsCarcinoma, Pancreatic Ductal +[4]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermanyUnited Kingdom

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBiontech Rna Pharmaceuticals Gmbh

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBiontech Rna Pharmaceuticals Gmbh

Active IndicationsN/A

Inactive IndicationsHead and Neck NeoplasmsPancreatic NeoplasmsCarcinoma, Pancreatic Ductal +[4]

Other Information

ATC CodeN/A